Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden.

Batyrbekova N, Aleman S, Lybeck C, Montgomery S, Duberg AS.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):63-70. doi: 10.1158/1055-9965.EPI-19-0769. Epub 2019 Nov 12.

2.

Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County.

Gahrton C, Westman G, Lindahl K, Öhrn F, Dalgard O, Lidman C, Nilsson LH, Said K, Duberg AS, Aleman S.

BMC Infect Dis. 2019 Nov 9;19(1):955. doi: 10.1186/s12879-019-4581-3.

3.

Management of hepatitis B virus infection, updated Swedish guidelines.

Westin J, Aleman S, Castedal M, Duberg AS, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R.

Infect Dis (Lond). 2020 Jan;52(1):1-22. doi: 10.1080/23744235.2019.1675903. Epub 2019 Oct 15.

PMID:
31613181
4.

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.

Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF.

Ann Intern Med. 2019 Sep 3;171(5):318-327. doi: 10.7326/M18-2753. Epub 2019 Aug 20.

PMID:
31426090
5.

Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.

Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J.

Scand J Gastroenterol. 2019 Aug;54(8):1042-1050. doi: 10.1080/00365521.2019.1652846. Epub 2019 Aug 19.

PMID:
31424972
6.

The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination.

Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV.

Clin Infect Dis. 2019 Nov 27;69(12):2218-2227. doi: 10.1093/cid/ciz714.

PMID:
31352481
7.

Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.

Lybeck C, Brenndörfer ED, Sällberg M, Montgomery SM, Aleman S, Duberg AS.

Eur J Gastroenterol Hepatol. 2019 Apr;31(4):506-513. doi: 10.1097/MEG.0000000000001316.

8.

Tissue-resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL-17.

Sobkowiak MJ, Davanian H, Heymann R, Gibbs A, Emgård J, Dias J, Aleman S, Krüger-Weiner C, Moll M, Tjernlund A, Leeansyah E, Sällberg Chen M, Sandberg JK.

Eur J Immunol. 2019 Jan;49(1):133-143. doi: 10.1002/eji.201847759. Epub 2018 Nov 14.

9.

IL13Rα2 expression identifies tissue-resident IL-22-producing PLZF+ innate T cells in the human liver.

Paquin-Proulx D, Greenspun BC, Pasquet L, Strunz B, Aleman S, Falconer K, Terabe M, Berzofsky JA, Sandberg JK, Melum E, Nixon DF, Björkström NK.

Eur J Immunol. 2018 Aug;48(8):1329-1335. doi: 10.1002/eji.201747334. Epub 2018 May 25.

10.

Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017.

Lagging M, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J; ; for the Swedish Consensus Group.

Infect Dis (Lond). 2018 Aug;50(8):569-583. doi: 10.1080/23744235.2018.1445281. Epub 2018 Mar 1. Review.

PMID:
29495923
11.

Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.

Hedenstierna M, Nangarhari A, El-Sabini A, Weiland O, Aleman S.

J Viral Hepat. 2018 Jul;25(7):802-810. doi: 10.1111/jvh.12879. Epub 2018 Mar 8.

PMID:
29406590
12.

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.

Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV; Hep-Nordic Study Group.

PLoS One. 2018 Jan 30;13(1):e0190146. doi: 10.1371/journal.pone.0190146. eCollection 2018.

13.

Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.

Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Westin J; Swedish Consensus Group.

Infect Dis (Lond). 2017 Aug;49(8):561-575. doi: 10.1080/23744235.2017.1300682. Epub 2017 Mar 15. Review.

PMID:
28293974
14.

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sällberg M, Lohmann V, Koh S, Bertoletti A, Chen M.

J Virol. 2017 Apr 13;91(9). pii: e00010-17. doi: 10.1128/JVI.00010-17. Print 2017 May 1.

15.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
16.

Long-term liver-related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders.

Holmström M, Nangarhari A, Öhman J, Duberg AS, Majeed A, Aleman S.

Haemophilia. 2016 Nov;22(6):e494-e501. doi: 10.1111/hae.13020. Epub 2016 Oct 5.

PMID:
27704656
17.

The hurdle with remaining risk for hepatocellular carcinoma in cirrhotic patients after a hepatitis C cure.

Aleman S.

Hepatol Med Policy. 2016 Sep 23;1:11. doi: 10.1186/s41124-016-0019-3. eCollection 2016.

18.

Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden.

Büsch K, Waldenström J, Lagging M, Aleman S, Weiland O, Kövamees J, Duberg AS, Söderholm J.

Scand J Gastroenterol. 2017 Jan;52(1):61-68. doi: 10.1080/00365521.2016.1228119. Epub 2016 Sep 6.

PMID:
27598393
19.

Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.

Hedenstierna M, Nangarhari A, Weiland O, Aleman S.

Clin Infect Dis. 2016 Sep 15;63(6):723-9. doi: 10.1093/cid/ciw362. Epub 2016 Jun 9.

PMID:
27282709
20.

Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.

Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Josephson F; Swedish Consensus Group.

Infect Dis (Lond). 2016 Apr;48(4):251-261. doi: 10.3109/23744235.2015.1113438. Epub 2015 Dec 1. Review.

21.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Hedenstierna M, Weiland O, Brass A, Bankwitz D, Behrendt P, Uhnoo I, Aleman S, Cardell K, Fryden A, Norkrans G, Eilard A, Glaumann H, Pietschmann T, Sällberg M, Brenndörfer ED.

Aliment Pharmacol Ther. 2015 Mar;41(6):532-43. doi: 10.1111/apt.13096. Epub 2015 Jan 28.

22.

The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.

Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S.

Scand J Gastroenterol. 2015 Feb;50(2):233-44. doi: 10.3109/00365521.2014.990505. Epub 2014 Dec 17.

PMID:
25515032
23.

"Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage".

Navarro-Illana P, Diez-Domingo J, Navarro-Illana E, Tuells J, Alemán S, Puig-Barberá J.

BMC Public Health. 2014 May 22;14:490. doi: 10.1186/1471-2458-14-490.

24.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
25.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005
26.

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ.

J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. Review.

PMID:
24713004
27.

Functional attributes of responding T cells in HCV infection: the recent advances in engineering functional antiviral T cells.

Pasetto A, Aleman S, Chen M.

Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):23-30. doi: 10.1007/s00005-013-0248-8. Epub 2013 Aug 18. Review.

PMID:
23955531
28.

A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.

Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R.

Clin Infect Dis. 2013 Jul;57(2):230-6. doi: 10.1093/cid/cit234. Epub 2013 Apr 24.

PMID:
23616492
29.

Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.

Rahbin N, Frelin L, Aleman S, Hultcrantz R, Sällberg M, Brenndörfer ED.

Biochem Biophys Res Commun. 2013 Mar 29;433(1):31-5. doi: 10.1016/j.bbrc.2013.02.075. Epub 2013 Feb 27.

PMID:
23454379
30.

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M.

J Immunol. 2012 Nov 1;189(9):4510-9. doi: 10.4049/jimmunol.1201613. Epub 2012 Sep 28.

31.

Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.

Lagging M, Duberg AS, Wejstål R, Weiland O, Lindh M, Aleman S, Josephson F; Swedish Consensus Group.

Scand J Infect Dis. 2012 Jul;44(7):502-21. doi: 10.3109/00365548.2012.669045. Epub 2012 Apr 16. Review.

PMID:
22506634
32.

Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.

Brenndörfer ED, Brass A, Söderholm J, Frelin L, Aleman S, Bode JG, Sällberg M.

Gut. 2012 Apr;61(4):589-96. doi: 10.1136/gut.2010.232116. Epub 2011 Aug 3.

PMID:
21813471
33.

Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population.

Aleman S, Endalib S, Stål P, Lööf L, Lindgren S, Sandberg-Gertzén H, Almer S, Olsson S, Danielsson A, Wallerstedt S, Hultcrantz R.

Scand J Gastroenterol. 2011 Sep;46(9):1118-26. doi: 10.3109/00365521.2011.591426. Epub 2011 Jun 15.

PMID:
21675821
34.

Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country.

Davídsdóttir L, Duberg AS, Törner A, Aleman S, Bäck E, Ekdahl K, Blaxhult A, Ekbom A, Hultcrantz R.

Scand J Gastroenterol. 2010 Aug;45(7-8):944-52. doi: 10.3109/00365521003770251.

PMID:
20384529
35.

The burden of hepatitis C in Sweden: a national study of inpatient care.

Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviðsdóttir L, Hultcrantz R, Bäck E, Ekdahl K, Montgomery SM.

J Viral Hepat. 2011 Feb;18(2):106-18. doi: 10.1111/j.1365-2893.2010.01276.x.

PMID:
20158602
36.

Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender.

Lidman C, Norden L, Kåberg M, Käll K, Franck J, Aleman S, Birk M.

Scand J Infect Dis. 2009;41(9):679-84. doi: 10.1080/00365540903062143. Erratum in: Scand J Infect Dis. 2009;41(9):684.

PMID:
19521924
37.

[Fibrosis indexes reduce the need of liver biopsy in chronic hepatitis C].

Björklund J, Aleman S, Weiland O.

Lakartidningen. 2009 Apr 1-7;106(14):1016-9. Swedish. No abstract available.

PMID:
19485036
38.

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grandér D, Frelin L, Sällberg M.

Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8.

39.

Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.

Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, Davidsdottir L, Hagen K, Hultcrantz R, Aleman S.

Scand J Gastroenterol. 2008;43(11):1378-86. doi: 10.1080/00365520802245395.

PMID:
18615358
40.

Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study.

Duberg AS, Törner A, Davidsdóttir L, Aleman S, Blaxhult A, Svensson A, Hultcrantz R, Bäck E, Ekdahl K.

J Viral Hepat. 2008 Jul;15(7):538-50. doi: 10.1111/j.1365-2893.2008.00982.x. Epub 2008 Apr 4.

PMID:
18397223
41.

Detection and characterization of focal liver lesions with contrast-enhanced ultrasonography in patients with hepatitis C-induced liver cirrhosis.

Rahbin N, Siösteen AK, Elvin A, Blomqvist L, Hagen K, Hultcrantz R, Aleman S.

Acta Radiol. 2008 Apr;49(3):251-7. doi: 10.1080/02841850701813831.

PMID:
18365808
42.

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.

Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, Aleman S, Nicolas D, Feu F, González-Pérez A, Borda A, Castro M, Poveda MJ, Arenas J; Investigators of the Asociación Española de Gastroenterología (AEG).

Am J Gastroenterol. 2007 Mar;102(3):507-15.

PMID:
17338735
43.

Minor nef gene alterations after human HIV-DNA immunisation.

Aleman S, Leitner T, Liu MA, Wahren B.

AIDS. 2004 Mar 26;18(5):817-9. No abstract available.

PMID:
15075520
44.

CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma.

Alcázar JL, Miranda D, Unanue A, Novoa E, Alemán S, Madariaga L.

Int J Gynaecol Obstet. 2004 Feb;84(2):173-4. No abstract available.

PMID:
14871524
45.

Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.

De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, Chiodi F.

Clin Exp Immunol. 2002 Mar;127(3):486-94. Erratum in: Clin Exp Immunol. 2003 Oct;134(1):167. D Fuchs [corrected to Fuchs D].

46.

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.

Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A.

AIDS. 2002 May 3;16(7):1039-44.

PMID:
11953470
47.

Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy.

Birk M, Aleman S, Visco-Comandini U, Sönnerborg A.

HIV Med. 2000 Oct;1(4):205-11.

48.

Human immunodeficiency virus type 1 variability and long-term non-progression.

Visco-Comandini U, Aleman S, Yun Z, Sönnerborg A.

J Biol Regul Homeost Agents. 2001 Jul-Sep;15(3):299-303.

PMID:
11693440
49.

[Autoimmune hepatitis with prolonged IGM antibodies to HAV. Are serological markers reliable in ruling out a diagnosis of autoimmune hepatitis?].

del Pozo D, Cano A, Peña E, Miquel J, Valer M, Alemán S, Merino J.

Gastroenterol Hepatol. 2001 Oct;24(8):387-9. Spanish.

PMID:
11674957
50.

[Surgical treatment of gastrointestinal stromal tumor].

Miquel Plaza J, Martín de Argila C, Peña E, del Pozo D, Aleman S, Boixeda D.

Rev Esp Enferm Dig. 2001 Mar;93(3):186. Spanish. No abstract available.

PMID:
11469079

Supplemental Content

Loading ...
Support Center